Owaidah Tarek M, Aljurf Mahmoud D
Department of Pathology, Laboratory of Tumor Immunology, King Faisal Specialist Hospital and Research Center, PO Box 3354, Riyadh 11211, Saudi Arabia.
Hematology. 2002 Oct;7(5):265-72. doi: 10.1080/1024533021000037180.
The approach for treatment of hematological cancers had changed in the last decade from non-specific eradication of tumor cells by chemotherapy to more specific strategies by activation of immune system. There are number of potential targets of immune responses in patients with hematological malignancies. Some have been developed like monoclonal antibody therapy and others that have yet to be define like dendritic cell infusion. In this review, we will discuss the evolving role of monoclonal antibody therapy and donor dendritic cell infusion in mounting on immune response in hematological malignancies.
在过去十年中，血液系统癌症的治疗方法已从通过化疗非特异性地根除肿瘤细胞转变为通过激活免疫系统的更具特异性的策略。血液系统恶性肿瘤患者存在许多免疫反应的潜在靶点。一些已经得到开发，如单克隆抗体疗法，而其他一些，如树突状细胞输注，尚未明确。在本综述中，我们将讨论单克隆抗体疗法和供体树突状细胞输注在引发血液系统恶性肿瘤免疫反应中不断演变的作用。
